Thrombocytosis: A paraneoplastic syndrome in patients with hepatocellular carcinoma

Table 1 Comparison of clinical and laboratory data, and tumor features between hepatocellular carcinoma (HCC) patients with and without thrombocytosis

	HCC patients with thrombocytosis (n = 31)	HCC patients without thrombocytosis (n = 1123)	P value
Age (yr)	52 ± 19	62 ± 12	< 0.001
Sex (male: female)	25:6	980:143	0.201
HBV: HCV: HBV + HCV-related	24:1:0	711:179:49	0.114
Mean Child-Pugh’s scores	7.2 ± 2.1	6.8 ± 2.2	0.336
Mean platelet counts (k/mm3)	484 ± 87	154 ± 80	< 0.001
Median (range)	441 (403-688)	133 (11-396)
Mean α-fetoprotein (ng/mL)	251042 ± 458734	57879 ± 212788	< 0.001
Median (range)	4859 (4-1892500)	252 (3-1621700)
Cirrhosis (+:-)	23:8	913:210	0.445
MPV tumor thrombosis (+:-)	11:20	171:952	0.005
Tumor metastases (+:-)	10:21	196:927	0.059
Tumor volumes %	63.5 ± 21.2	30.7 ± 26.9	< 0.001
Both lobes with tumor involvements (+:-)	22:9	439:684	< 0.001
Therapy for HCC (+:-)	10:21	583:540	0.048
Mean survival (d)	144 ± 208	373 ± 521	< 0.001
Median (range)	77 (4-852)	147 (2-3666)

Data were expressed as mean ± SD. HBV: hepatitis B virus, HCV: hepatitis C virus, MPV: main portal vein.